2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 912

Urate Lowering Therapy in Moderate to Severe Chronic Kidney Disease
Abstract Number: 913

Aggregatibacter Actinomycetemcomitans-Induced Hypercitrullination Links Periodontal Infection to Autoimmunity in Rheumatoid Arthritis
Abstract Number: 914

Longitudinal Blood Transcriptomics Uncovers Immune Networks Associated with Complications in Lupus Pregnancy
Abstract Number: 915

Establishment of a Powerful Method to Identify Autoantigens Expressed on the Cell Surface
Abstract Number: 916

Novel Immunosignature Stratifies Patients with Rheumatoid Arthritis into Distinct Disease Sub-Groups and Predicts Response to Anti-Tnfα Therapies
Abstract Number: 917

B Cells Inhibit Osteoblast Differentiation in Inflammatory Arthritis
Abstract Number: 918

Anergic B Cells May Preserve Peripheral Tolerance in Lupus-Prone Congenic Mice
Abstract Number: 919

IL-17 Receptor a Signaling Impedes NF-ĸB p50/p50 Repressor and Subverts B-Cell Anergy in BXD2 Mice
Abstract Number: 920

Autoantigen-Specific T Cell and Antibody Reactivity to a Human Gut Commensal in Antiphospholipid Syndrome
Abstract Number: 921

The Anti-IL-17A Antibody Secukinumab (Cosentyx®, AIN457) Diminishes the Expression of the NFκB Pathway Modulator Iκbζ
Abstract Number: 922

Negative Regulation of IL-17 Receptor Signaling By Regnase-1 Limits Immunopathology in a Mouse Model of Psoriatic Skin Disease
Abstract Number: 923

Retinoic Acid Inhibits Expression of Interleukin 9 By Altering Enhancer Architecture
Abstract Number: 924

Intestinal Dysbiosis Influences Gut-Joint Lymphocyte Trafficking
Abstract Number: 925

Complement C5a Receptor Is the Key Initiator of Neutrophil Adhesion and Inflammation in Immune Complex-Induced Arthritis
Abstract Number: 926

Increased Concentration of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Predate Onset of Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].